Home/Pipeline/MAX-001

MAX-001

Acute and Chronic Pain

Phase 2Active

Key Facts

Indication

Acute and Chronic Pain

Phase

Phase 2

Status

Active

Company

Maxona Pharmaceuticals

About Maxona Pharmaceuticals

Maxona Pharmaceuticals is a private, clinical-stage company developing non-opioid, non-NSAID pain therapies. Its lead asset, MAX-001, is an optimized formulation of a molecule with a long history of safe use outside the U.S., currently advancing through clinical trials with Phase II completion expected in 2025. The company is led by a seasoned team with expertise in CNS disorders, drug development, and commercialization, targeting the massive and urgent unmet need in the pain management market.

View full company profile

Therapeutic Areas

Pain Management Neurology

Other Acute and Chronic Pain Drugs

Drug	Company	Phase	Status
KNX101	Kinoxis Therapeutics	Preclinical/IND‑enabling	Active
NTM-006	Neumentum	Phase 2	Active
Pain Therapy Portfolio	Molteni Farmaceutici	Approved	Active